ArticleInternational journal of genomics2026
Advancing Prognosis Prediction and Immunotherapy Efficacy in Lung Adenocarcinoma Through Machine Learning: Novel Insights From Anoikis Regulator Patterns in Single-Cell Multiomics.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing Prognosis Prediction and Immunotherapy Efficacy in Lung Adenocarcinoma Through Machine Learning: Novel Insights From Anoikis Regulator Patterns in Single-Cell Multiomics.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anoikis, a type of programmed cell death induced by detachment from the extracellular matrix (ECM), is crucial in cancer progression. Resistance to anoikis often correlates with enhanced invasion, metastasis, treatment resistance, and tumor recurrence. However, no research has systematically explored anoikis-regulated tumor microenvironment (TME) in lung adenocarcinoma (LUAD). Methods: We used single-cell RNA sequencing (scRNA-seq) and spatial transcriptome RNA sequencing (stRNA-seq) analyses to reveal the subtype of anoikis-related epithelial cells, demonstrating its spatial location characteristics. With the maker genes of prognostic significance, we depicted the molecular landscapes of anoikis regulator patterns in RNA-seq data. We developed the anoikis-related signature (Anoikis.Sig) by integrating 10 machine learning (ML) algorithms to accurately predict prognosis in LUAD. Based on the median risk score computed by Anoikis.Sig, patients were divided into high- and low-risk groups. We employed extensive analysis between two risk groups, in terms of clinic implications, immune microenvironment, somatic mutations, immunotherapy, chemotherapy, and single-cell landscape. Finally, we verified the prognosis value of two Anoikis.Sig model genes. Results: By integrative analysis of scRNA-seq and stRNA-seq datasets, we defined diverse function subtypes of anoikis-related epithelial cells and investigated their spatial regulator patterns. Through its marker genes and leave-one-out cross-validation, we utilized the RSF algorithm to develop the Anoikis.Sig with a superior predictive ability, outperformed other LUAD signatures and clinical indicators. We categorized LUAD patients into high- and low-risk groups, which demonstrated the low-risk group had a better survival outcome, an ample immune infiltration, a distinct mutational landscape, and response to immunotherapy. ScRNA-seq analysis revealed biologically intercellular disparities delineated by Anoikis.Sig. qRT-PCR validated the prognostic value of two model genes of Anoikis.Sig in LUAD. Conclusion: Through multiomics analyses and ML algorithms, we succeeded in establishing the Anoikis.Sig to efficiently predict prognosis in Anoikis.Sig, which delineated molecular landscapes of anoikis regulator patterns and clinical applications of Anoikis.Sig.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.